Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A

14-11-2013 Business Wire HealthComments (0)

BaxterPharmaceutical

Baxter announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top